These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26583826)

  • 1. [Risk-adapted anticoagulation in atrial fibrillation in Germany, Austria and Switzerland - an analysis from the PREFER-in-AF study].
    Steffel J; Gwechenberger M; Müller MW; Ammentorp B; Darius H; Kirchhof P
    Dtsch Med Wochenschr; 2015 Nov; 140(23):e247-55. PubMed ID: 26583826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation.
    Lip GY; Laroche C; Boriani G; Cimaglia P; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Popescu MI; Tica O; Hellum CF; Mortensen B; Tavazzi L; Maggioni AP
    Europace; 2015 Jan; 17(1):24-31. PubMed ID: 24957921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF).
    Kirchhof P; Ammentorp B; Darius H; De Caterina R; Le Heuzey JY; Schilling RJ; Schmitt J; Zamorano JL
    Europace; 2014 Jan; 16(1):6-14. PubMed ID: 24084680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry.
    Königsbrügge O; Simon A; Domanovits H; Pabinger I; Ay C
    BMC Cardiovasc Disord; 2016 Dec; 16(1):254. PubMed ID: 27938343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry.
    Le Heuzey JY; Ammentorp B; Darius H; De Caterina R; Schilling RJ; Schmitt J; Zamorano JL; Kirchhof P
    Thromb Haemost; 2014 May; 111(5):833-41. PubMed ID: 24651882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.
    Guo Y; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):71-8. PubMed ID: 23466969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
    Gorczyca-Michta I; Wożakowska-Kapłon B
    Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances].
    Gorzelak P; Zyzak S; Krewko Ł; Mozdzan M; Broncel M
    Pol Merkur Lekarski; 2014 May; 36(215):302-6. PubMed ID: 24964505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation in "real world" patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study.
    Volterrani M; Iellamo F; Rosano G; Guarini P; Pusineri E; Bonassi S; Chimini C; Zaccà F; Proto C;
    Int J Cardiol; 2013 Oct; 168(5):4729-33. PubMed ID: 23948115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antithrombotic management in atrial fibrillation].
    Fauchier L; Taillandier S; Clementy N
    Rev Prat; 2013 Feb; 63(2):199, 201-6. PubMed ID: 23513780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.
    Di Biase L; Burkhardt JD; Santangeli P; Mohanty P; Sanchez JE; Horton R; Gallinghouse GJ; Themistoclakis S; Rossillo A; Lakkireddy D; Reddy M; Hao S; Hongo R; Beheiry S; Zagrodzky J; Rong B; Mohanty S; Elayi CS; Forleo G; Pelargonio G; Narducci ML; Dello Russo A; Casella M; Fassini G; Tondo C; Schweikert RA; Natale A
    Circulation; 2014 Jun; 129(25):2638-44. PubMed ID: 24744272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.